4. Evaluation of clinical responses to immunotherapy.
| N | Analysed | Method | CA‐125 | Tumour | Overall conclusion | |||
| Response definition | Results | Definition for tumour response | Results | |||||
| Antonilli 2016 | 10 | yes | tumour | unknown | Cohort 1 (baseline status; disease free): 1× PD and 6× NED Cohort 2 (baseline status; recurrent disease): 3× PD |
6× NED 4× PD |
||
| Baumann 2011 | 45 | yes | both | Gynaecologic Cancer Intergroup Guidelines (evaluable patients: cohort 1: 7; cohort 2: 3) | Cohort 1: 7× ↑, Cohort 2: 3× ↑ | RECIST | Cohort 1: 2× SD, 21× PD Cohort 2: 1× PR, 5× SD, 16× PD |
Cohort 1: 2× SD, 21× PD Cohort 2: 1× PR, 5× SD, 16× PD |
| Braly 2009 | 18/22 | yes | unknown | unknown | complete clinical remission 15×/18× | |||
| Brossart 2000 | 3 | yes | unknown | 2× SD, 1× PD | ||||
| Chianese‐Bullock 2008 | 9 | yes | both | unknown | unknown | 1× NED, 8× PD | ||
| Chu 2012 | 11 | yes | both | unknown | unknown | 3× PD, 7× NED | ||
| Dhodapkar 2012 | 6 | yes | unknown | not reported | ||||
| Diefenbach 2008 | 9 | yes | both | unknown | unknown | not reported | ||
| Dijkgraaf 2015 | 6 | yes | both | Gynaecologic Cancer Intergroup Guidelines | Cohort 3 (n = 6): 4× PD, 2× PR | RECIST | Cohort 3 (n = 6): 2× PR, 3× PD, 1× SD | Cohort 3: 2× PR, 3× PD, 1× SD |
| Ehlen 2005 | 13 | yes | both | decrease > 15% (↓); < 15% change (=) stable; > 15% increase (↑) | 4× ↓, 1× =, 6× ↑ | unknown | 3× SD, 10× PD | |
| Freedman 1998 | 30 | yes | unknown | 18× SD, 10× PD | ||||
| Galanis 2010 | 21 | yes | both | Gynaecologic Cancer Intergroup Guidelines | 2× ↓, 3× =, 16× ^? | RECIST | 14× SD, 7× PD | 14× SD, 7× PD |
| Gordon 2004 | 20 | yes | both | unknown | 6× ↓ | unknown | 2× NED, 2× CR, 1× PR, 1× SD, 9× PD | |
| Gribben 2005 | 6 | yes | unknown | 6× PD | ||||
| Gulley 2008 | 3 | yes | both | unknown | unknown | not reported | ||
| Imhof 2013 | 15 | yes | unknown | not reported | ||||
| Kaumaya 2009 | 5 | yes | unknown | 2× SD, 3× PD | ||||
| Kawano 2014 | 42 | yes | tumour | RECIST | 1× CR, 3× SD, 21× PD | 1× CR, 3× SD, 21× PD | ||
| Kobayashi 2014 | 56 | yes | tumour | RECIST 3 months after first vaccination | 2× PR, 14× SD, 32× PD Disease controle rate: 29% Objective response rate: 3.6% |
PR: 3.6%, SD: 25%, PD: 57% | ||
| Le 2012 | 2 | yes | tumour | RECIST | 2× PD | 2× PD | ||
| Leffers 2009a | 20 | yes | both | Gynaecologic Cancer Intergroup Guidelines | not reported | RECIST | not reported | 2× SD, 18× PD |
| Lennerz 2014 | 7 | yes | tumour | RECIST | 5× PD, 2× NE | 5× PD | ||
| Letsch 2011 | 8 | yes | unknown | 4× SD, 4× PD | ||||
| MacLean 1992 | 10 | yes | unknown | 3× SD, 7× PD | ||||
| Method 2002 | 102 | yes | unknown | not reported | ||||
| Mohebtash 2011 | 14 | yes | unknown | 1× SD, 11× PD | ||||
| Nicholson 2004 | 26 | yes | CA‐125 | unknown | 21× PD, 1× SD, 1× lost to follow‐up, 3× unknown | |||
| Odunsi 2007 | 18 | yes | tumour | unknown | 1× CR, 17× unknown | |||
| Odunsi 2014 | 12 | yes | tumour | RECIST | 1× PD, 5× SD | PD: 10%, SD:50% | ||
| Ohno 2009 | 6 | yes | both | unknown | not reported | RECIST | 1× SD, 3× PD | 1× SD, 4× PD, 1× withdrawal |
| Peethambaram 2009 | 4 | yes | tumour | unknown | 2× SD, 2× PD | 2× SD, 2× PD | ||
| Rahma 2012 | 21 | yes | both | unknown | not reported | RECIST | Cohort 1: 2× NED, 11× PD Cohort 2: 2× NED, 5× PD |
Cohort 1: 2× NED, 11× PD Cohort 2: 2× NED, 5× PD |
| Reinartz 2004 | 119 | yes | tumour | WHO | not reported | |||
| Sabbatini 2006 | 42 | yes | both | unknown | unknown | 12× SD, 21× PD, 9× withdrawal (6× PD) | ||
| Sabbatini 2012 | 28 | yes | tumour | RECIST | Cohort 1: 1× NED, 3× PD Cohort 2: 3× NED, 10× PD Cohort 3: 2× NED, 9× PD |
Cohort 1: 1× NED, 3× PD Cohort 2: 3× NED, 10× PD Cohort 3: 2× NED, 9× PD |
||
| Ströhlein 2009 | 2 | yes | both | unknown | unknown | 1× PD, 1× PR or SD | ||
| Suzuki 2016 | 32 | yes | tumour | RECIST | 12 months: PR: 2/32, PD: 28/32 | 2× PR, 28× PD | ||
| Takeoka 2017 | 2 | yes | tumour | RECIST | 2× PD | 2× PD | ||
| Takeuchi 2013 | 38 | yes | tumour | RECIST | 1× CR, 2× PR, 10× SD, 9× PD | 1× CR, 2× PR, 10× SD, 9× PD | ||
| Tsuda 2004 | 5 | yes | both | unknown | WHO | 4× PD, 1× SD | ||
| van Zanten‐Przybysz 2002 | 5 | yes | both | unknown | 1× ↓, 1× =, 1× ↑, 2× unknown | unknown | 1× NED, 1× SD, 2× PD, 1× unknown | 3× PD, 2× SD |
| Vermeij 2012 | 12 | yes | both | Gynaecologic Cancer Intergroup Guidelines | 7× ↓/=, 3× ↑ | RECIST | not reported | 2× SD, 8× PD |
| Wagner 1993 | 58 | yes | CA‐125 | unknown | not reported | |||
| Berek 2001 | 252 | no | ||||||
| Berek 2004 | 145 | no | ||||||
| Berek 2009 | 371 | no | ||||||
| Berinstein 2012 | 6 | no | ||||||
| Berinstein 2013 | 19 | no | ||||||
| Buzzonetti 2014 | 129 | no | ||||||
| Goh 2013 | 63 | no | ||||||
| Gray 2016 | 56 | no | ||||||
| Heiss 2010 | 129 | no | ||||||
| Ma 2002 | 4 | no | ||||||
| MacLean 1996 | 34 | no | ||||||
| Möbus 2003 | 44 | no | ||||||
| Morse 2011 | 8 | no | ||||||
| Nishikawa 2006 | 4 | no | ||||||
| Noujaim 2001 | 184 | no | ||||||
| O'Cearbhaill 2016 | 24 | no | ||||||
| Odunsi 2012 | 22 | no | ||||||
| Pfisterer 2006 | 36 | no | ||||||
| Sabbatini 2000 | 25 | no | ||||||
| Sabbatini 2007 | 11 | no | ||||||
| Sabbatini 2013 | 888 | no | ||||||
| Sabbatini 2017 | 171 | no | ||||||
| Sandmaier 1999 | 7 | no | ||||||
| Schultes 1998 | 75 | no | ||||||
C1: cohort 1. C2: cohort 2. C3: cohort 3. CA‐125: cancer antigen‐125. CR: complete response. GCIG: Gynecologic Cancer Intergroup. NED: no evidence of disease. PD: progressive disease. PR: partial response. RECIST: Response Evaluation Criteria In Solid Tumors. SD: stable disease. WHO: World Health Organization.